

Anthony Dawes
Anthony Dawes (European Commission, Brussels): Since December 2011, Anthony Dawes is a member of the Legal Service of the European Commission. Previously, he was an associate at White & Case LLP Brussels from September 2007 to November 2011.
Linked author
438 | Conferences
Articles
29680 Bulletin
1182
This article is the winner of the business category, anticompetitive practices section of the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. In an Opinion delivered on 10 February 2011, Advocate General (‘AG’) Sharpston of the European Court of (...)
802
The English High Court (Floyd J) refuses to make a reference to the Court of Justice of the European Union (‘ECJ’) concerning the circumstances in which an English court can make a declaration of non-liability for breach of Article 101 TFEU where a company is the subject of an ongoing European (...)
1203
The High Court of England and Wales has declined to issue a stay against a damage claim brought by tyre manufactures seeking redress from members of an alleged Butadiene Rubber and Emulsion Styrene Butadiene Rubber cartel. Background The damage claim brought by the tyre manufacturers follows (...)
1429
The Court of Appeal of England & Wales has upheld a High Court judgment that a co-operative joint venture between certain racecourse owners for the supply of images, sound and data to licensed betting offices in the United Kingdom in respect of horse races held at their racecourses is not (...)
1611
In striking out a representative claim brought on behalf of “all other direct or indirect purchasers of air freight services”, the English High Court has refused to stretch the scope of the English civil procedure rules in order to facilitate the bringing of such damages actions. Background The (...)
2506
Introduction In December 2008, the UK Office of Fair Trading (“OFT”) published revised guidance (“the Guidance”) for undertakings and individuals that are contemplating applying for leniency in cartel cases , which sets out the OFT’s position on a number of important leniency-related issues. (...)
2766
In two separate cases involving the same claimant, the High Court of England and Wales has referred questions to the European Court of Justice regarding whether the prohibition on the use of foreign satellite decoder equipment and cards in the UK infringes, inter alia, Article 81 EC. (...)
3713
In the context of a ruling on jurisdiction, which determined that a UK company is not bound by the terms of a German settlement agreement relating to a patent dispute, the English High Court considers, without deciding the issue, whether a no-challenge provision in a patent settlement agreement (...)
5857
The High Court’s judgment is the first time that an English court has to consider what type of damages can be obtained in claims following from an infringement decision by the European Commission in competition cases. According to the judgment, a claimant is only entitled to compensatory damages (...)
3866
The Court of Appeal of England and Wales has ruled that restitutionary damages are not generally available in antitrust cases and that, in most cases, compensatory damages provide adequate remedies. Background In 2001, the European Commission adopted a decision finding that a number of (...)
4745
The Office of Fair Trading (OFT) has issued an interim measures direction to the London Metal Exchange (LME) under section 35 of the Competition Act 1998. This is the first time that the OFT has employed these powers. The interim measures direction prevents LME from extending the trading hours (...)
7213 Review
2444
The EU judicial review of the Commission’s decisions generates an abundant case law. This Trends aims to clarify the major difficulties that arise from the concept of "unlimited jurisdiction" and that manifest themselves both at the level of the control standard to which the Commission’s (...)
4769
On 8 July 2009, the European Commission’s released its long-awaited Final Report on its Pharmaceutical Sector Inquiry. The Final Report suggests that the shortcomings of the regulatory framework are a key explanatory factor for delayed generic entry and limited innovation. Meanwhile the Final (...)